Shi Yuanhui, Chen Yuye, Xiao Zihao, Wang Yajie, Fu Cong, Cao Yuhan
Department of Nephrology, Yi Ji Shan Hospital Affiliated to Wan Nan Medical College, Wuhu, Anhui, China.
Anesthesia Laboratory and Training Center of Wannan Medical College, Wuhu, Anhui, China.
J Cell Mol Med. 2025 Jan;29(1):e70335. doi: 10.1111/jcmm.70335.
Renal fibrosis (RF) is a crucial pathological factor in the progression of chronic kidney disease (CKD) to end-stage renal failure, and accurate and noninvasive assays to monitor the progression of renal fibrosis are needed. Circular RNAs (circRNAs) are noncoding RNAs that can be used as diagnostic biomarkers and therapeutic targets for human diseases. In this study, we analysed the expression of hsa_circ_0008925 in human urinary renal tubular cells and investigated its role in renal fibrosis. Urinary samples were collected from CKD patients with varying degrees of renal fibrosis; renal tubular epithelial cells were isolated from the urinary samples using magnetic bead sorting. In patients with moderate-severe renal fibrosis, the expression of hsa_circ_0008925 in urinary renal tubular epithelial cells was elevated compared to that in patients with no renal fibrosis to mild renal fibrosis. Spearman correlation analysis indicated that the hsa_circ_0008925 expression was positively correlated with serum creatinine (Scr, rs = 0.424, p = 0.031). The expression of hsa_circ_0008925 was elevated in TGF-β1-treated HK-2 cells in vitro. Silencing of hsa_circ_0008925 using siRNA inhibited TGF-β1-induced fibrosis in HK2 cells. RNA pull-down and mass spectrometric analyses indicated that serine/arginine-rich splicing factor 6 (SRSF6) is the downstream of hsa_circ_0008925. Silencing mmu_circ_0002215 and inhibiting SRSF6 alleviated renal fibrosis in a UUO model in vivo. Inhibiting hsa_circ_0008925/SRSF6 alleviated renal fibrosis in vitro and in vivo. These findings suggest that targeting the hsa_circ_0008925/SRSF6 pathway could hold promise as a potential therapeutic strategy for treating renal fibrosis.
肾纤维化(RF)是慢性肾脏病(CKD)进展至终末期肾衰竭的关键病理因素,因此需要准确且无创的检测方法来监测肾纤维化的进展。环状RNA(circRNAs)是非编码RNA,可作为人类疾病的诊断生物标志物和治疗靶点。在本研究中,我们分析了hsa_circ_0008925在人尿肾小管细胞中的表达,并研究了其在肾纤维化中的作用。收集了不同程度肾纤维化的CKD患者的尿液样本;使用磁珠分选从尿液样本中分离肾小管上皮细胞。与无肾纤维化至轻度肾纤维化的患者相比,中重度肾纤维化患者尿肾小管上皮细胞中hsa_circ_0008925的表达升高。Spearman相关性分析表明,hsa_circ_0008925表达与血清肌酐(Scr,rs = 0.424,p = 0.031)呈正相关。体外实验中,TGF-β1处理的HK-2细胞中hsa_circ_0008925的表达升高。使用siRNA沉默hsa_circ_0008925可抑制TGF-β1诱导的HK2细胞纤维化。RNA下拉和质谱分析表明,富含丝氨酸/精氨酸的剪接因子6(SRSF6)是hsa_circ_0008925的下游分子。沉默mmu_circ_0002215并抑制SRSF6可减轻体内单侧输尿管梗阻(UUO)模型中的肾纤维化。抑制hsa_circ_0008925/SRSF6可在体外和体内减轻肾纤维化。这些发现表明,靶向hsa_circ_0008925/SRSF6通路有望成为治疗肾纤维化的潜在治疗策略。